In an attempt to improve upon the 43%-48% regression rates noted for various CAP regimens consisting of cyclophosphamide,doxorubicin (Adriamycin), and cis-diamminedichloroplatinum(II) in various doses and schedules, triazinate was added to tht three-drug combination, and the new combination (T-CAP) was evaluated inpatients with advanced adenocarcinoma of the lung.(T-CAP) produced a regression rate of 57% with a 7-week increase in overall median time to progression and a 4-weeks incrase in overall median survival compared to the best of the CAP schedules. More stomatitis and dermatitis were noted with he new combination, but myelosuppression was similar to that of the CAP regimens. These data suggest that further studies wih triazinate should be conducted in patients with adenocarcinoma of the lung.
|Original language||English (US)|
|Number of pages||4|
|Journal||Cancer Treatment Reports|
|State||Published - Dec 1 1980|
ASJC Scopus subject areas
- Cancer Research